Express Pharma

Lupin receives FDA approval for Methylprednisolone Tablets

4

These tablets are used to treat endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, allergic states, ophthalmic diseases and respiratory diseases, among others

Pharma major Lupin announced that it has received approval for its Methylprednisolone Tablets USP, 2 mg, 4 mg, 8 mg, 16 mg and 32 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Pharmacia and Upjohn’s Medrol tablets, 2 mg, 4 mg, 8 mg, 16 mg and 32 mg.

Lupin’s Methylprednisolone Tablets USP, 2 mg, 4 mg, 8 mg, 16 mg, and 32 mg, is the generic version of Pharmacia and Upjohn’s Medrol Tablets, 2 mg, 4 mg, 8 mg, 16 mg and 32 mg. It is indicated to treat endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, acute exacerbations of multiple sclerosis, tuberculous, meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy, trichinosis with neurologic or myocardial involvement.

Methylprednisolone Tablets had annual sales of approximately $114.3 million in the US (IQVIA MAT December 2018).

Comments are closed.